These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 34596484)

  • 1. Comparison of stent related symptoms in patients taking mirabegron, solifenacin, or tamsulosin: A double blinded randomized clinical trial.
    Chandna A; Kumar S; Parmar KM; Sharma AP; Devana SK; Mete UK; Singh SK
    Urologia; 2022 Nov; 89(4):589-596. PubMed ID: 34596484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of ureteral catheter related symptoms; mirabegron versus tamsulosin/solifenacin combination: A randomized controlled trial.
    Sahin A; Yildirim C; Yuksel OH; Urkmez A
    Arch Esp Urol; 2020 Jan; 73(1):54-59. PubMed ID: 31950924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A critical assessment of the effects of tamsulosin and solifenacin as monotherapies and as a combination therapy for the treatment of ureteral stent-related symptoms: a 2 × 2 factorial randomized trial.
    Park J; Yoo C; Han DH; Shin DW
    World J Urol; 2015 Nov; 33(11):1833-40. PubMed ID: 25809877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Mirabegron plus Tamsulosin and Tamsulosin Monotherapy for the Treatment of Ureteral Stent-Related Symptoms: A Prospective Randomized Study.
    Zhang K; Yan W; Li H; Chen J; Wang Q; Chai Y; Yuan L; Zhu G
    Urol Int; 2022; 106(12):1226-1232. PubMed ID: 36244331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized controlled trial comparing alpha blocker (tamsulosin) and anticholinergic (solifenacin) in treatment of ureteral stent-related symptoms.
    El-Nahas AR; Tharwat M; Elsaadany M; Mosbah A; Gaballah MA
    World J Urol; 2016 Jul; 34(7):963-8. PubMed ID: 26453222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mirabegron vs. solifenacin in control of endoscopically inserted ureteral stent-related symptoms.
    Abdelaziz AS; Salama NM; Ghoneem AM
    World J Urol; 2022 Aug; 40(8):2113-2119. PubMed ID: 35760910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tamsulosin, Solifenacin, and Their Combination for the Treatment of Stent-Related Symptoms: A Randomized Controlled Study.
    Dellis AE; Papatsoris AG; Keeley FX; Bamias A; Deliveliotis C; Skolarikos AA
    J Endourol; 2017 Jan; 31(1):100-109. PubMed ID: 27809592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does tamsulosin or mirabegron improve ureteral stent-related symptoms? A prospective placebo-controlled study.
    Yavuz A; Kilinc MF; Aydin M; Ofluoglu Y; Bayar G
    Low Urin Tract Symptoms; 2021 Jan; 13(1):17-21. PubMed ID: 32408390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does mirabegron relieve ureteric stent-related discomfort? A prospective, randomized, multicentre study.
    Tae BS; Cho S; Jeon BJ; Choi H; Park JY; Cho SY; Lee KC; Bae JH
    BJU Int; 2018 Nov; 122(5):866-872. PubMed ID: 29802800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of solifenacin, as monotherapy or combination with tamsulosin in ureteral stent-related symptoms: a systematic review and meta-analysis.
    Wang J; Zhang X; Zhang T; Mu J; Bai B; Lei Y
    World J Urol; 2017 Nov; 35(11):1669-1680. PubMed ID: 28550362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of mirabegron versus solifenacin as additional therapy for persistent OAB symptoms after tamsulosin monotherapy in men with probable BPO.
    Soliman MG; El-Abd SA; Tawfik AM; Radwan MH; El-Abd AS
    World J Urol; 2021 Jun; 39(6):2049-2054. PubMed ID: 32869151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tamsulosin Monotherapy Is Effective in Reducing Ureteral Stent-related Symptoms: A Meta-analysis of Randomized Controlled Studies.
    Chen YB; Gao L; Jiang Q; Ran K; Luo RT
    Curr Med Sci; 2019 Oct; 39(5):707-718. PubMed ID: 31612387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of tamsulosin hydrochloride in relieving "double-J ureteral stent-related morbidity": a randomized placebo controlled clinical study.
    Singh I; Tripathy S; Agrawal V
    Int Urol Nephrol; 2014 Dec; 46(12):2279-83. PubMed ID: 25201459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of tamsulosin oral-controlled absorption system, solifenacin, and combined therapy for the management of ureteric stent-related symptoms.
    Abdelaal AM; Al-Adl AM; Abdelbaki SA; Al Azab MM; Al Gamal KA
    Arab J Urol; 2016 Jun; 14(2):115-22. PubMed ID: 27489738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient-reported outcomes from SYNERGY, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with monotherapy and placebo in OAB patients.
    Robinson D; Kelleher C; Staskin D; Mueller ER; Falconer C; Wang J; Ridder A; Stoelzel M; Paireddy A; van Maanen R; Hakimi Z; Herschorn S
    Neurourol Urodyn; 2018 Jan; 37(1):394-406. PubMed ID: 28704584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does Combination Therapy with Tamsulosin and Tolterodine Improve Ureteral Stent Discomfort Compared with Tamsulosin Alone? A Double-Blind, Randomized, Controlled Trial.
    Sivalingam S; Streeper NM; Sehgal PD; Sninsky BC; Best SL; Nakada SY
    J Urol; 2016 Feb; 195(2):385-90. PubMed ID: 26393904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of pregabalin in relieving ureteral stent-related symptoms: a randomized controlled clinical trial.
    Ragab M; Soliman MG; Tawfik A; Abdel Raheem A; El-Tatawy H; Abo Farha M; Magdy M; Elashry O
    Int Urol Nephrol; 2017 Jun; 49(6):961-966. PubMed ID: 28260223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of solifenacin and tamsulosin may provide additional beneficial effects for ureteral stent-related symptoms-outcomes from a network meta-analysis.
    Jian Z; Chen Y; Liu Q; Liao B; Yang T; Li H; Wang K
    World J Urol; 2019 Feb; 37(2):289-297. PubMed ID: 30030658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study).
    Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K
    BJU Int; 2015 Oct; 116(4):612-22. PubMed ID: 25639296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mirabegron for the Treatment of Ureteral Stent-related Symptoms: A Systematic Review and Meta-analysis.
    Van Besien J; Keller EX; Somani B; Pietropaolo A; Claessens M; Merckx L; Tailly T; De Coninck V
    Eur Urol Focus; 2022 Jul; 8(4):1031-1041. PubMed ID: 34688588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.